반응식
C1(CCCN2CCN(C3C=C(F)C(OC)=CC=3F)CC2)CCCCC1.[C:26]([C:30]1[CH:35]=[CH:34][C:33]([C:36](=[O:56])[CH2:37][CH2:38][CH2:39][N:40]2[CH2:45][CH2:44][N:43]([C:46]3[CH:51]=[C:50]([F:52])[C:49]([O:53]C)=[CH:48][C:47]=3[F:55])[CH2:42][CH2:41]2)=[CH:32][CH:31]=1)([CH3:29])([CH3:28])[CH3:27]>>[C:26]([C:30]1[CH:35]=[CH:34][C:33]([C:36](=[O:56])[CH2:37][CH2:38][CH2:39][N:40]2[CH2:45][CH2:44][N:43]([C:46]3[CH:51]=[C:50]([F:52])[C:49]([OH:53])=[CH:48][C:47]=3[F:55])[CH2:42][CH2:41]2)=[CH:32][CH:31]=1)([CH3:29])([CH3:27])[CH3:28]참가 물질
3
실험 절차
Production Example 94 was repeated except that 1-(3-cyclohexylpropyl)-4-(2,5-difluoro-4-methoxyphenyl)piperazine was replaced with 1-(4-tert-butylphenyl)-4-[4-(2,5-difluoro-4-methoxyphenyl)piperazin-1-yl]butan-1-one (330 mg). The resulting crude product was purified on TLC (developer, ethyl acetate: hexane=2:1) to provide 1-(4-tert-butylphenyl)-4-[4-(2,5-difluoro-4-hydroxyphenyl)piperazin-1-yl]butan-1-one (146 mg).
후처리
- customThe resulting crude product was purified on TLC (developer, ethyl acetate: hexane=2:1)
출처 및 근거
- ORD 기록
- ord-04100dbdd2e84cd0b5b8eed414d74221
- 출처 데이터셋
- uspto-grants-2008_11
- 특허 번호
- US07449466B2
연결된 노트
불러오는 중…